Christian Roesky, Ph.D.

Managing Director/Chief Executive Officer

Dr. Roesky was appointed CEO & Managing Director of Novaliq effective November 1, 2016. He brings to Novaliq more than 15 years in the field of eye care as well as extensive operational experience at multiple international healthcare companies. Previously, Dr. Roesky was General Manager for the D-A-CH region of Bausch + Lomb GmbH in Berlin; Commercial Director Central Europe of Abbott’s Diagnostics Division, General Manager and speaker of the German Country Management Board of Abbott GmbH & Co. KG in Wiesbaden from 2013 – 2015; and, General Manager of Alcon Germany & Austria (Novartis) from 2009-2013.

Prior to his general management assignments, Dr. Roesky worked as Marketing Manager EURMEA for Alcon in USA, Spain and Switzerland focusing on strategy and market access to transform global and regional commercial activities. He (had previously) studied chemistry in Bonn and Freiberg, both Germany, and was awarded Ph.D. with honors from the Technical University of Freiberg in Germany.

Oliver Schlüter Ph.D.

Managing Director/Chief Financial Officer

Dr. Schlüter was CFO of CureVac GmbH from xx to xx. During his tenure at CureVac, he was instrumental for the transformation of a 70 employee R&D-driven company to a 170-employee customer-centric and value-focused corporation that entered into several strategic partnerships with in-house cGMP-manufacturing.

From the time of his appointment in 2010, the company secured more than €200 million in funding and increased the company value more than tenfold to more than €1 billion. Dr. Schlüter has 20 years of professional experience within the fields of Finance and Life Sciences. He holds a PhD in computational finance and also studied business administration.

Bernhard Günther Dipl.-Ing. (FH)

Co-Founder, Chief Innovation Officer

Bernhard Günther founded Novaliq as Chief Executive Officer in January 2007. He has more than 20 years of experience in the field of ophthalmic biopharmaceutics and medical devices. Prior to Novaliq, Mr. Günther served as Chief Executive Officer of Fluoron GmbH, a German medical device company, which pioneered the development of proprietary ophthalmic Biomaterials for the treatment of severe retinal diseases.

During his tenure at Fluoron, Mr. Günther transformed the company to an internationally leading manufacturer of unique intraocular endotamponades and staining solutions.

Mr Günther serves as a supervisory board member of the Geuder AG Group und holds a Diploma in Polymer Engineering from the University of Applied Sciences in Darmstadt, Germany.

Hartmut Voss Ph.D.

Chief Business Officer

Dr. Voss has 30 years of experience within the field of Life Sciences and has spent more than 15 years as an entrepreneur, holding various senior management positions within the Biotechnology Industry. He is responsible for the scientific evaluation of biotechnology and biopharmaceutical companies at dievini Hopp BioTech holding GmbH & Co. KG for more than 10 years. At Novaliq he leads all business and business development activities since 2015.

Following his studies in biology at the University of Kaiserslautern, Dr. Voss obtained his PhD from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. In 1997, he co-founded LION bioscience AG (now SYGNIS Pharma AG) and in 2004, Life Biosystems GmbH (now Molecular Health GmbH), where he held various senior management positions.

Frank Löscher Ph.D.

Chief Technology Officer

Dr. Frank Löscher joined Novaliq in early 2014.

He has 20 years of experience in the pharmaceutical industry in the areas of Research, Development, Project Management, Business Development and licensing. Dr. Löscher covers the full range from active ingredient chemistry to pharmaceutical product development and drug product manufacturing.

As part of the executive board at Novaliq Dr. Löscher is responsible for the areas of research, development and commercial production (CMC).

He graduated from Ruprecht Karls University in Heidelberg with a degree in Chemistry and later received his Ph.D. in Biophysical Chemistry at the University of Regensburg.